Analysts Set ADMA Biologics Inc (NASDAQ:ADMA) Price Target at $18.67

ADMA Biologics Inc (NASDAQ:ADMA) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $18.6667.

Several brokerages have weighed in on ADMA. Canaccord Genuity Group reduced their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Mizuho decreased their price target on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Finally, Raymond James Financial assumed coverage on ADMA Biologics in a research report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price target for the company.

ADMA Biologics News Roundup

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: No company-specific positive catalyst was reported in the latest news batch; the main focus remains on litigation risk.
• Neutral Sentiment: ADMA short-interest data was reported as unchanged/limited, offering little clear trading signal on its own.
• Negative Sentiment: Several law firms announced or reiterated securities-fraud class actions against ADMA Biologics, adding legal uncertainty and potential financial risk. Article Title
• Negative Sentiment: Reports alleging channel stuffing and misrepresentations about growth expectations may further damage investor confidence in ADMA Biologics. Article Title

Insider Buying and Selling at ADMA Biologics

In other news, Director Jerrold B. Grossman bought 12,500 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the acquisition, the director owned 513,884 shares of the company’s stock, valued at $4,116,210.84. The trade was a 2.49% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 3.90% of the company’s stock.

Institutional Trading of ADMA Biologics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Summit Securities Group LLC purchased a new position in shares of ADMA Biologics during the fourth quarter valued at approximately $29,000. Western Wealth Management LLC bought a new stake in shares of ADMA Biologics during the 1st quarter worth approximately $31,000. iSAM Funds UK Ltd bought a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $34,000. Optima Capital LLC purchased a new position in ADMA Biologics during the 4th quarter valued at $36,000. Finally, Morse Asset Management Inc purchased a new position in ADMA Biologics during the 4th quarter valued at $44,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Price Performance

ADMA stock opened at $8.27 on Wednesday. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $20.46. The firm has a market capitalization of $1.92 billion, a P/E ratio of 12.16 and a beta of 0.73. The company has a fifty day simple moving average of $8.48 and a two-hundred day simple moving average of $11.94. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The firm had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. During the same period in the previous year, the firm posted $0.11 EPS. The business’s quarterly revenue was down .3% on a year-over-year basis. Analysts anticipate that ADMA Biologics will post 0.8 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.